干扰素β-话题@MedSci

#干扰素β#

16篇内容 | 1144人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1530131, encodeId=679f153013174, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者病情无显著改善作用, objectType=article, longId=207064, objectId=90bb20e064a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90bb20e064a9, replyNumber=0, likeNumber=59, createdTime=2021-02-13, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90bb20e064a9, moduleTitle=NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者病情无显著改善作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90bb20e064a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530130, encodeId=58081530130ab, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者无明显治疗作用, objectType=article, longId=204094, objectId=9fe52040944a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fe52040944a, replyNumber=0, likeNumber=66, createdTime=2020-12-05, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fe52040944a, moduleTitle=NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者无明显治疗作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fe52040944a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530129, encodeId=61c4153012992, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=Lancet respirat med：雾化吸入干扰素β-1a可大大改善新冠肺炎患者病情并加速恢复, objectType=article, longId=203344, objectId=2f45203344f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f45203344f4, replyNumber=0, likeNumber=78, createdTime=2020-11-15, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f45203344f4, moduleTitle=Lancet respirat med：雾化吸入干扰素β-1a可大大改善新冠肺炎患者病情并加速恢复, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f45203344f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530128, encodeId=bce71530128fe, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征, objectType=article, longId=201940, objectId=9263201940fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9263201940fd, replyNumber=0, likeNumber=60, createdTime=2020-10-12, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9263201940fd, moduleTitle=NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9263201940fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530127, encodeId=757e153012e0b, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=美国国立卫生研究院（NIH）进行瑞德西韦联合干扰素β-1a治疗COVID-19的临床试验, objectType=article, longId=198946, objectId=a877198946d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a877198946d5, replyNumber=0, likeNumber=62, createdTime=2020-08-09, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a877198946d5, moduleTitle=美国国立卫生研究院（NIH）进行瑞德西韦联合干扰素β-1a治疗COVID-19的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a877198946d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530126, encodeId=c506153012638, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=吸入型干扰素β制剂SNG001降低COVID-19发展为重症的风险, objectType=article, longId=197836, objectId=0dea19e83681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0dea19e83681, replyNumber=0, likeNumber=93, createdTime=2020-07-22, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0dea19e83681, moduleTitle=吸入型干扰素β制剂SNG001降低COVID-19发展为重症的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0dea19e83681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530125, encodeId=40941530125df, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=Lancet：含干扰素β-1b的抗病毒“鸡尾酒疗法”对轻中症新冠患者有效, objectType=article, longId=194027, objectId=1b3a19402e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b3a19402e11, replyNumber=0, likeNumber=52, createdTime=2020-05-14, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b3a19402e11, moduleTitle=Lancet：含干扰素β-1b的抗病毒“鸡尾酒疗法”对轻中症新冠患者有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b3a19402e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530124, encodeId=3f4e153012416, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效, objectType=article, longId=193897, objectId=c69119389efc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c69119389efc, replyNumber=0, likeNumber=80, createdTime=2020-05-12, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c69119389efc, moduleTitle=Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c69119389efc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530123, encodeId=96801530123de, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=JAMA：干扰素β对急性呼吸窘迫综合征患者预后的影响, objectType=article, longId=188858, objectId=bdda18885861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdda18885861, replyNumber=0, likeNumber=76, createdTime=2020-02-28, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdda18885861, moduleTitle=JAMA：干扰素β对急性呼吸窘迫综合征患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdda18885861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530122, encodeId=373e15301227b, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=NEJM：芬戈莫德与干扰素β-1a对儿童多发性硬化症的疗效比较, objectType=article, longId=148777, objectId=3e5c148e7712, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5c148e7712, replyNumber=0, likeNumber=80, createdTime=2018-09-14, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5c148e7712, moduleTitle=NEJM：芬戈莫德与干扰素β-1a对儿童多发性硬化症的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5c148e7712)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530121, encodeId=7b0c153012116, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=NEJM：复发性多发性硬化症治疗奥瑞珠单抗与干扰素β-1a，哪家强？, objectType=article, longId=85090, objectId=262c8509025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262c8509025, replyNumber=0, likeNumber=83, createdTime=2016-12-23, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262c8509025, moduleTitle=NEJM：复发性多发性硬化症治疗奥瑞珠单抗与干扰素β-1a，哪家强？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262c8509025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530120, encodeId=92c0153012037, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=ECTRIMS 2016：百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta疗效显著优于Avonex（干扰素β-1a）, objectType=article, longId=78356, objectId=ead2e8356ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ead2e8356ce, replyNumber=0, likeNumber=72, createdTime=2016-09-26, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ead2e8356ce, moduleTitle=ECTRIMS 2016：百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta疗效显著优于Avonex（干扰素β-1a）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ead2e8356ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530119, encodeId=1b5e153011988, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=NEJM：治疗复发性多发性硬化症，达珠单抗HYP优于干扰素β-1α, objectType=article, longId=56988, objectId=34c7569889d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34c7569889d, replyNumber=0, likeNumber=62, createdTime=2015-10-10, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34c7569889d, moduleTitle=NEJM：治疗复发性多发性硬化症，达珠单抗HYP优于干扰素β-1α, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34c7569889d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530118, encodeId=9f4015301186a, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=Nat Immuno：干扰素β/IFNAR1激活免疫机制, objectType=article, longId=21877, objectId=2c48218e764, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c48218e764, replyNumber=0, likeNumber=71, createdTime=2013-07-25, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c48218e764, moduleTitle=Nat Immuno：干扰素β/IFNAR1激活免疫机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c48218e764)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530117, encodeId=c29a153011ebb, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=JAMA：干扰素β治疗多发性硬化症与患者伤残进展减少无关, objectType=article, longId=7999, objectId=e6e6e9999b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6e6e9999b, replyNumber=0, likeNumber=58, createdTime=2012-07-21, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6e6e9999b, moduleTitle=JAMA：干扰素β治疗多发性硬化症与患者伤残进展减少无关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6e6e9999b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530116, encodeId=35a1153011652, content=<a href='/topic/show?id=171c48e20d5' target=_blank style='color:#2F92EE;'>#干扰素β#</a>, objectTitle=干扰素β-1a早期治疗可控制MS进展（REFLEXION试验）, objectType=article, longId=5745, objectId=bbfa5e4508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbfa5e4508, replyNumber=0, likeNumber=67, createdTime=2012-04-27, rootId=0, userName=huiwelcome, userId=c8bc12021096, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbfa5e4508, moduleTitle=干扰素β-1a早期治疗可控制MS进展（REFLEXION试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbfa5e4508)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

干扰素β

2020-05-29

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者病情无显著改善作用

2021-02-13

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

NEJM：瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者无明显治疗作用

2020-12-05

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

Lancet respirat med：雾化吸入干扰素β-1a可大大改善新冠肺炎患者病情并加速恢复

2020-11-15

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征

2020-10-12

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

美国国立卫生研究院（NIH）进行瑞德西韦联合干扰素β-1a治疗COVID-19的临床试验

2020-08-09

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

吸入型干扰素β制剂SNG001降低COVID-19发展为重症的风险

2020-07-22

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

Lancet：含干扰素β-1b的抗病毒“鸡尾酒疗法”对轻中症新冠患者有效

2020-05-14

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效

2020-05-12

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

JAMA：干扰素β对急性呼吸窘迫综合征患者预后的影响

2020-02-28

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

NEJM：芬戈莫德与干扰素β-1a对儿童多发性硬化症的疗效比较

2018-09-14

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

NEJM：复发性多发性硬化症治疗奥瑞珠单抗与干扰素β-1a，哪家强？

2016-12-23

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

ECTRIMS 2016：百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta疗效显著优于Avonex（干扰素β-1a）

2016-09-26

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

NEJM：治疗复发性多发性硬化症，达珠单抗HYP优于干扰素β-1α

2015-10-10

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

Nat Immuno：干扰素β/IFNAR1激活免疫机制

2013-07-25

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

JAMA：干扰素β治疗多发性硬化症与患者伤残进展减少无关

2012-07-21

huiwelcome (审核中...)

前往app查看评论内容

#干扰素β#

干扰素β-1a早期治疗可控制MS进展（REFLEXION试验）

2012-04-27

科室
- - 订阅+
  - 更多科室
工具
服务